# DEVELOPMENT OF RABBITMONOCLONAL ANTIBODIES FOR INDIANFLYING FOX (BAT) BIOMARKERS

> **NIH NIH N43** · AVANTGEN, INC. · 2024 · $592,751

## Abstract

In this phase I project, the Offeror proposes to use his novel proprietary platform to discover high-affinity, highly specific, rabbit monoclonal antibodies (mAbs) against a panel of six bat immune markers. Once the mAb clones are produced and characterized, the Offeror will use them to develop sandwich ELISA assays for cytokines and flow cytometry assays for cytokine receptors for investigators to detect the expression of these bat antigens in primary bat cells or samples. If successful, these reagents will help us better understand the immune responses of bats after viral infections and support a NIAID research priority.

## Key facts

- **NIH application ID:** 11219378
- **Project number:** 75N93024C00039-0-9999-1
- **Recipient organization:** AVANTGEN, INC.
- **Principal Investigator:** XIAOMIN FAN
- **Activity code:** N43 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $592,751
- **Award type:** —
- **Project period:** 2024-09-01 → 2026-08-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/11219378

## Citation

> US National Institutes of Health, RePORTER application 11219378, DEVELOPMENT OF RABBITMONOCLONAL ANTIBODIES FOR INDIANFLYING FOX (BAT) BIOMARKERS (75N93024C00039-0-9999-1). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/11219378. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*